Faith E. Davies is the director of the Center for Blood Cancers at NYU Langone’s Perlmutter Cancer Center. She leads efforts to enhance their clinical and translational research programs for blood cancers. She also serve as director of the Clinical Myeloma Program at Perlmutter Cancer Center, where she treats patients who have blood cancer, particularly multiple myeloma, a type of cancer that originates in bone marrow plasma cells and can affect the bones, kidneys, and blood. Dr. Davies see people who are newly diagnosed with multiple myeloma as well as those who have relapsed disease, or have the related conditions such as smoldering myeloma, monoclonal gammopathy of undetermined significance (MGUS), and amyloidosis. When a patient comes to her for care, she develops an individual treatment plan by learning everything she can about the person, including examining his or her symptoms and conducting a laboratory analysis of the myeloma cells. She believes that it’s important to craft a good roadmap and apply laboratory-based research to patient care. She treats every person as unique, and at each point in the journey, she assess whether we are on the right path or if we need to adjust the treatment plan. Dr. Davies research focuses on the biology and treatment of myeloma and related conditions. Throughout her career, she has worked to examine potential new drugs and genetic technologies that can be used to treat myeloma more effectively. With clinical trials, she hopes to explore new ways to diagnose and treat these conditions—she is keen to do away with invasive bone marrow diagnostic tests and replace them with blood tests or imaging. Dr. Davies has published more than 350 peer-reviewed articles in leading journals, and is an active member of the American Association for Cancer Research and the American Society of Hematology. She is passionate about patient education and advocacy, and speaks regularly at international meetings.

Rafael Fonseca is the Chief Innovation Officer, Director of the Mayo Clinic Cancer Center. He is a hematologist who specializes in the care and research of multiple myeloma and related conditions. Dr. Fonseca earned his medical degree at Universidad Anahuac, Mexico. He completed a residency in Internal Medicine at the University of Miami, Florida, and a fellowship in Hematology and Oncology at Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota. Dr. Fonseca has served in many leadership capacities at Mayo Clinic including Director for the Mayo Clinic Comprehensive Cancer Center (Interim, Enterprise) and Associate Director for the Center of Individualized Medicine (Arizona) and Chair of the Department of Internal Medicine (Arizona). Most notably, he is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at the institution. Dr. Fonseca's practice focuses on diagnosing and treating plasma cell disorders. He participates and leads clinical trials that have led to the approval of various drugs for the treatment of myeloma. His efforts include translational research, clinical research and clinical care. Dr. Fonseca led a team of researchers that characterized the clinical implications of genetic markers in myeloma. He also has expertise in myeloma bone disease, prognostic markers, pharmacoeconomics and new drug development. His laboratory is also focused on development of new drugs and understanding their mechanisms of action. Dr. Fonseca's research has been funded by the National Cancer Institute (R01, P01, SPORE), the Leukemia and Lymphoma Society, the Multiple Myeloma Research Fund, and the Damon Runyon Cancer Research Fund. He has given many national and international presentations as a visiting professor, and has authored numerous articles (over 300), book chapters, editorials, abstracts and letters. He has an H index 114, with 48418 citations (Google Scholar accessed 9/2020). Throughout his training and career, Dr. Fonseca has received numerous awards and honors, including the Damon Runyon-Walter Winchell Clinical Investigator Award and the International Waldenström Macroglobulinemia Research Award.

Irene Ghobrial is the Senior Vice President for Experimental Medicine, Director of the Center for Early Detection and Interception of Blood Cancers, Co-Leader of the Lymphoma/Myeloma Cancer Center Program, Lavine Family Chair for Preventative Cancer Therapies, Director of the Ghobrial Lab, and Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School. Her research focuses on precursor conditions of multiple myeloma, aiming to understand genetic, epigenetic, and immune mechanisms of disease progression, identify novel biomarkers, and develop therapies to eliminate disease before progression. She has led 15+ clinical trials in Waldenstrom macroglobulinemia and multiple myeloma precursor conditions. Dr. Ghobrial received her MD in 1995 from Cairo University School of Medicine, Egypt.  She completed her Internal Medicine training at Wayne State University, Mich., and her Hematology/Oncology subspecialty training at Mayo Clinic College of Medicine, Minn.  She joined Dana-Farber in the field of Waldenstrom's macroglobulinemia and multiple myeloma in 2005.

Dr. Landgren is a Professor of Medicine, Chief of the Myeloma Division, and Director of the Sylvester Myeloma Institute. He is a Co-Leader with Dr. Jaime Merchan of the Translational and Clinical Oncology (TCO) Program at NCI-designated Sylvester Comprehensive Cancer Center (Sylvester). Dr. Merchan and Dr. Landgren complement each other's talents and strengths and serve as key conduits to move science from the lab into the clinic and vice versa. As a Cancer Center Support Grant member, Dr. Landgren participates in research activities as an independent investigator and as a leader of research governance committees, and serve on multi-disciplinary research teams. Dr. Landgren leads the clinical and research operations as well as the development of the Myeloma Program at Sylvester and his career highlights include: Strong track record in drug development Served as a principal investigator for a large number of clinical trials Principal Investigator for the Myeloma Genomic Research Laboratory at Sylvester Comprehensive Cancer Center Designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease to multiple myeloma

Gareth Morgan is the Director of multiple myeloma research at NYU Langone’s Perlmutter Cancer Center. He has a particular focus on disease prevention strategies and treating patients with high-risk disease and relapsed disease. He also treats pre-myeloma conditions, including smoldering multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS), and related disorders such as Waldenstrom macroglobulinemia, a rare blood cancer caused by excess of abnormal white blood cells in the bone marrow. Dr. Morgan uses the latest technology and his specialized knowledge of genetics to “fingerprint” and distinguish the different types of multiple myeloma. This helps create tailored therapeutic approaches to various subtypes of melanoma. Customizing therapy in this way can more precisely target the cancerous cells and achieve the best outcomes with minimum side effects. He also researches the precursor stages of disease with the aim of early diagnosis and prevention of early or more advanced stage myeloma. Over the last few years, there has been tremendous progress in multiple myeloma treatment, and he strives to bring these advances to the clinic as soon as possible. He has pioneered studies on the genetics and treatment of multiple myeloma and has published more than 500 peer-reviewed articles in leading journals. He also speaks regularly at major scientific meetings. He leads clinical trials and study the molecular mechanisms related to multiple myeloma with the aim of targeting novel treatments and cellular therapies that improve outcomes.

Robert Orlowski is Chairman, Ad Interim, Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, where he is board-certified in medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. After his fellowships in Hematology and Medical Oncology at John Hopkins Sidney Kimmel Comprehensive Cancer Center, he joined the faculty at the University of North Carolina in Chapel Hill. Following that, Dr. Orlowski accepted a position at The University of Texas MD Anderson Cancer Center in 2007 to lead the Myeloma Section in the Department of Lymphoma/Myeloma. His research interests include the pathobiology of novel therapeutic targets and mechanisms of drug resistance in myeloma, which are documented in hundreds of scientific articles, book chapters, and presentations at conferences. Dr. Orlowski is an investigator on numerous clinical trials and was appointed Myeloma Committee Chair for SWOG.

Noopur Raje is the Director of the Center for Multiple Myeloma in the Mass General Cancer Center. Dr Raje earned her MD from BJ Medical College, University of Pune in Pune, Maharashtra, India. She is passionate about research to better understand multiple myeloma growth and improve treatments for this rare cancer. After completing her residency at Mass General and a fellowship at Dana-Farber Cancer Institute, she returned to Mass General where she established her own lab to investigate multiple myeloma. Her lab comprises a translational research program to evaluate new therapies with a focus on myeloma bone disease biology. Dr Raje's work explores the bone marrow microenvironment to find new targets for treatments that will stop tumor growth. Her research also strives to understand the factors that cause bone disease in patients with myeloma. Dr Raje is a member of the International Myeloma Working Group and National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines Committee for Multiple Myeloma. In 2010, she received the Claflin Distinguished Scholar award at Mass General. In 2013, she was named the first incumbent of the Rita M Kelley Chair in Oncology at Mass General. In 2017, she received the Leukemia and Lymphoma Society Clinical Scholar Award.

Eytan M. Stein is Chief of Leukemia Service, and the Director of Program for Drug Development in Leukemia. He specializes in caring for people with acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. He is also an active clinical researcher who develops new and innovative approaches to treating acute myeloid leukemia (AML). Dr. Stein is the principal investigator on a wide variety of clinical trials for people with AML. He is working to develop new therapies — such as small molecule inhibitors — that can more precisely and effectively target AML. His goal as a doctor and researcher is to help people with AML and other blood cancers have the best possible outcomes.

Dr. Mims Co-leads the Leukemia and Hematologic Malignancies Program who specializes in treating patients suffering from acute and chronic myeloid diseases, particularly acute myeloid leukemia (AML). She was named to the Castle Connolly list of “Regional Top Doctors” in 2019, as well as being rated in the top 10 percent of physicians in the nation for patient satisfaction in 2017. Dr. Mims received my medical degree and Master of Science in Clinical Research (MSCR) from the Medical University of South Carolina and then completed a combined fellowship in medical oncology/translational research here at The Ohio State University, where she currently serve as a professor in the Division of Hematology. During her fellowship, she received the Conquer Cancer Foundation Young Investigator Award, the American Society of Hematology Clinical Research Training Institute Award and a T32 Research Training Grant from the National Institutes of Health. She has received the American Society of Hematology Clinical Scholar Award and the Alliance Foundation Clinical Scholar Award, both for research support. As a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, Dr. Sims research interests include studying the effectiveness of novel therapeutics on patients with AML and other myeloid neoplasms. She has authored multiple clinical trial proposals in AML and has been the site principal investigator (PI) for investigator-initiated and industry-supported AML studies in both upfront and relapsed/refractory disease. She is currently the lead PI on a multi-center study investigating novel treatment in elderly AML patients though the Leukemia & Lymphoma Society Beat AML Master Trial. Additionally, her work has been published in several well-respected journals, including Molecular Pharmacology, Leukemia and Blood.

Dr. Naval Daver is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (MDACC) in Houston, TX. He is a clinical investigator with a focus on molecular and immune therapies in acute myeloid leukemia (AML) and myeloid disease and is principal investigator on more than 25 ongoing institutional, national, and international clinical trials in these diseases, including multiple registration and label enabling trials. These trials focus on developing a personalized therapy approach by targeting specific mutations or immune pathways expressed by patients with AML, evaluating novel combinations of targeted, immune, and cytotoxic agents, and identifying and overcoming mechanisms of resistance. He is especially interested in developing monoclonal and bispecific antibodies, immune checkpoint, CD47, NK and T-cell based approaches, as well as combinations of targeted and apoptotic therapies in AML, and he is leading a number of these trials at MDACC. Dr. Daver has published more than 400 peer-reviewed manuscripts and is on the editorial board of numerous hematology journals. He also serves as Chair on numerous national and international meetings and educational platforms.